Trial · NCT03646123
Results by group384
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 384
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Febrile Neutropenia (FN) Rate (Part A) | Part A | Any treatment-emergent FN | 5 | Participants | |
| Febrile Neutropenia (FN) Rate (Part A) | Part A | Treatment-related treatment-emergent FN | 5 | Participants | |
| Febrile Neutropenia (FN) Rate (Part A) | Part A | Grade 3 or higher treatment-emergent FN | 5 | Participants | |
| Febrile Neutropenia (FN) Rate (Part A) | Part A | Grade 3 or higher treatment-related treatment-emergent FN | 5 | Participants | |
| Complete Response (CR) Rate at EOT (Parts B and C) | Part B | 88 | 95% Confidence Interval 76.3 to 94.9 | Percentage of participants | |
| Complete Response (CR) Rate at EOT (Parts B and C) | Part C | 92 | 95% Confidence Interval 86.0 to 95.4 | Percentage of participants | |
| Number of Participants With Adverse Events of Clinical Interest (AECI) (Part A) | Part A | 32 | Participants | ||
| Primary Refractory Disease Rate (Part A) | Part A | 10 | 95% Confidence Interval 2.8 to 23.7 | percentage of participants | |
| Complete Response Rate (Part A) | Part A | 80 | 95% Confidence Interval 64.4 to 90.9 | percentage of participants | |
| Physician-reported Progression Free Survival (PFS) (Part A) | Part A | 89.23 | 95% Confidence Interval 73.76 to 95.82 | percentage of participants | |
| Number of Participants With Subsequent Anticancer Therapy Utilization (Part A) | Part A | Participants with any subsequent therapy | 6 | Participants | |
| Number of Participants With Subsequent Anticancer Therapy Utilization (Part A) | Part A | Consolidative radiotherapy: Radiotherapy | 3 | Participants | |
| Number of Participants With Subsequent Anticancer Therapy Utilization (Part A) | Part A | Consolidative radiotherapy: Proton radiation | 1 | Participants | |
| Number of Participants With Subsequent Anticancer Therapy Utilization (Part A) | Part A | Immunotherapy: Nivolumab | 1 | Participants | |
| Number of Participants With Subsequent Anticancer Therapy Utilization (Part A) | Part A | Maintenance: Nivolumab | 1 | Participants | |
| Number of Participants With Subsequent Anticancer Therapy Utilization (Part A) | Part A | Maintenance radiotherapy: Radiation therapy | 1 | Participants | |
| Number of Participants With Subsequent Anticancer Therapy Utilization (Part A) | Part A | Systemic therapy for progressive disease: Bendamustine monotherapy | 1 | Participants | |
| Number of Participants With Subsequent Anticancer Therapy Utilization (Part A) | Part A | Systemic therapy for relapsed disease: Nivolumab | 1 | Participants | |
| Actual Dose Intensity: Brentuximab Vedotin (Part A) | Part A | 0.5 | Standard Deviation 0.1 | mg/kg/week | |
| Actual Dose Intensity: Doxorubicin, Vinblastine, Dacarbazine (Part A) | Part A | Doxorubicin | 11.8 | Standard Deviation 1.0 | mg/m2/week |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03646123/results